Figures & data
Figure 1. Effect of continuous and protracted (i.e. 4-day) exposure of Estramustine (A), Temozolomide (B), Paclitaxel (C), and Compound 5h (D) on in vitro cell growth to determine therapeutic drug ranges. The growth of untreated control cells was taken as 100% and the growth of treated populations of cells was expressed as % of this. Columns and bars represent mean values +/− SE, respectively. Negative growth figures indicate that cell number after treatment was lower than cell number prior to treatment. For relevant statistical analyses, refer to main text.
Figure 2. Effect of low-dose Estramustine (A), Temozolomide (B) and Paclitaxel (C) in combination with IMC-1C11 (25 µg/ml) on in vitro HUVEC growth compared with single-drug schedule, following continuous, 4-day exposure. The growth of untreated control cells was taken as 100% and the growth of treated populations of cells was expressed as % of this. Columns and bars represent mean values +/− SE, respectively. *p < 0.05 comparing combinational regime to single-drug schedule (synergistic effect).
Figure 3. Effect of low-dose Estramustine (A), Temozolomide (B) and Paclitaxel (C) in combination with Compound 5h (0.1 µM) on in vitro HUVEC growth compared with single-drug schedule, following continuous, 4-day exposure. The growth of untreated control cells was taken as 100% and the growth of treated populations of cells was expressed as % of this. Columns and bars represent mean values +/− SE, respectively. *p < 0.05 comparing combinational regime to single-drug schedule (synergistic effect), †p < 0.05 comparing combinational regime to single-drug schedule (additive effect), ‡p < 0.05 comparing combinational regime to single-drug schedule.
